Abstract. Increasing evidence has indicated that long non-coding RNAs (lncRNAs) were aberrantly expressed and acted as key regulators in various types of disease, including cancer. lncRNA cancer susceptibility 2 (CASC2) has been found to be downregulated and acts as a tumor suppressor in various type of cancer, including gastric cancer (GC).
Introduction
Gastric cancer (GC) is the fourth most commonly diagnosed type of cancer and the second leading cause of global cancer-associated mortality worldwide (1, 2) . Although advances in surgical techniques, radiotherapy and chemotherapy have been made in the treatment of GC over the past two decades, the prognosis for GC patients remains poor due to many patients being diagnosed at an advanced stage with extensive invasion and lymphatic metastasis, and the majority develop regional or distant recurrences (3, 4) . Previous studies have identified many genes closely associated with GC progress, although the underlying complex molecular mechanisms remain obscure. Therefore, an improved understanding of the molecular mechanisms underlying GC may improve the diagnosis and therapy of patients with GC.
Long non-coding RNAs (lncRNAs) are a class of single-stranded RNA molecules >200 nucleotides without protein-coding capacity (5, 6) . Increasing evidence demonstrated that lncRNAs are critical in multiple biological processes, including cell growth, cell differentiation, cell apoptosis and cell invasion (7) (8) (9) (10) . For example, it has been found that lncRNA-HOX transcript antisense RNA was upregulated in diffuse large B cell lymphoma, and correlated with an invasive phenotype and poor prognosis (7) . Furthermore, a reduction of lncRNA GAS5 was identified as an independent prediction factor for overall survival (OS; calculated from the date of surgery to the date of death due to any cause or last follow-up), and overexpression of GAS5 suppressed the cell proliferation and invasion ability (8) .
The lncRNA, small nucleolar RNA cancer susceptibility 2 (CASC2), located at chromosome 10q26, was originally identified as a downregulated gene and acted as a tumor suppressor gene in endometrial cancer (11) . CASC2 was downregulated in glioma tissues, and overexpression of CASC2 inhibited cell proliferation, migration and invasion via negative regulation of miR-21 (12) . In a recent study, it was indicated that lncRNA CASC2 expression levels were significantly decreased in GC (13) ; however, the clinical significance and biological functions of CASC2 in GC remain unclear.
The present study first determined the expression and clinicopathological features of CASC2 in GC tissue, and then investigated its biological functions and associated mechanisms by overexpression of CASC2.
Materials and methods
Patient samples. A total of 69 fresh GC tissue specimens, together with matched adjacent non-tumorous tissue specimens, were collected from patients who underwent surgery at the Xiaogang Hospital (Ningbo, China) between May 2011 and June 2012. Written consent to use the samples for research was obtained from all patients prior to surgery. None of the patients received preoperative therapy prior to surgical resection. The histologic diagnosis of tumors was performed by at least two experienced pathologists based on the World Health Organization criteria (14) . All samples were immediately frozen following resection in liquid nitrogen and stored at -80˚C until RNA extraction. Cell proliferation analysis. The capability of cellular proliferation was assessed via Cell Counting Kit-8 assay (Dojingdo Molecular Technologies, Inc., Kumamoto, Japan). Approximately 3x10 3 cells transfected with control vector or CASC2 were seeded into 96-well culture plates. CCK-8 solution (10 µl) was added and incubated at 37˚C for 2 h and maintained for 24, 48, 72 and 96 h. Finally, the absorbance at a wavelength of 450 nm was measured using a spectrophotometer reader (Elx800; BioTek Instruments, Inc., Winooski, VT, USA). All experiments were performed as 5 replicates and were repeated 3 times independently.
RNA extraction, reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA from the frozen samples and cell lines was extracted using Invitrogen TRIzol reagent; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. cDNA from all samples was synthesized from 500 ng total RNA using a PrimeScript ® 1st strand cDNA Synthesis kit (Takara Biotechnology Co., Ltd., Dalian, China) on an ABI 9700 DNA thermal cycler (Applied Biosystems; Thermo Fisher Scientific, Inc.) following the manufacturer's protocols. qRT-PCR analyses were performed using an SYBR Premix EX Taq™ II kit (Biotechnology Co., Ltd.) on the ABI Prism 7900. The thermal cycling conditions involved initial denaturation for 10 sec at 94˚C, followed by 40 cycles of 5 sec at 94˚C and 30 sec at 60˚C. The PCR primers for CASC2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were as follows: Forward, 5'-GCT GAT CAG AGC ACA TTG GA-3' and reverse 5'-ATA AAG GTG GCC ACA ACT GC-3' for CASC2; forward, 5'-ACC CAC TCC TCC ACC TTT GAC-3' and reverse, 5'-TGT TGC TGT AGC CAA ATT CGT T-3' for GAPDH. The expression level of CASC2 was calculated using the 2 −ΔΔCq method and normalized to the respective GAPDH expression level (15) . The specificity of each PCR reaction was confirmed by melting curve analyses.
Cell apoptosis analysis. For the apoptosis assays, cells were harvested with trypsin enzyme and washed with phosphate-buffered saline 48 h after transfection. Annexin-V-fluorescein isothiocyanate and propidium iodide (BD Biosciences, Franklin Lakes, NJ, USA) were added to stain the cells according to the manufacturer's protocols. Finally, Apoptotic cells were measured with a Beckman Coulter FC500 (Beckman Coulter, Inc., Brea, CA, USA) and analyzed using FlowJo version 10.07 (FlowJo LLC, Ashland, OR, USA).
Endothelial tube formation in vitro. GC cells were transfected with control vector or pcDNA-CASC2. After transfection (48 h), the supernatants were collected and centrifuged at 14,000 x g for 30 min at 4˚C to discard cell debris. The supernatant was harvested for further investigations. A tube formation assay was performed as previously described (16) . HUVECs were cultured in conditioned medium from the supernatant of the GC cells at a density of 20,000 cells per well in a 96-well plate precoated with 150 µl Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). The HUVECs were cultured at 37˚C in a 5% CO 2 atmosphere for 6 h. The formation of HUVEC tubular structures was calculated and imaged under a light microscope (Olympus Corp., Tokyo, Japan) at a magnification of x100. Cell invasion assay. To assess the cell motility ability in vitro, transwell chambers with 8-µm pore polycarbonate membranes (Corning Incorporated, Corning, NY, USA) were used. Following transfection (24 h), cells were collected and re-suspended in 100 µl serum-free medium, and seeded on the Matrigel-coated upper chamber. The lower chamber contained complete medium as a chemoattractant. Following 48 h incubation at 37˚C, the cells on the lower side of the membrane were fixed and stained with 0.5% crystal violet solution (Beyotime Institute of Biotechnology, Haimen, China). Five fields of vision were randomly selected and cell numbers were counted under a light microscope (Olympus Corp.).
Statistical analysis. All data are expressed as the mean ± standard deviation of at least three independent experiments. The difference between two groups was estimated using Student's t-test. The χ 2 test was used to assess the association between the expression of CASC2 and clinicopathological features. The OS rates were analyzed using the Kaplan-Meier method, with the log-rank test applied for comparison. All statistical analyses were performed using SPSS version 11.5 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

lncRNA CASC2 expression levels decreased in GC samples and cell lines.
Previous studies indicated that the expression level of CASC2 was decreased in GC tissues and colorectal cancer (13, 17) . The expression level of lncRNA CASC2 was initially confirmed in GC tissue samples and the results indicated that the relative expression of CASC2 in GC tissue was significantly decreased compared with the non-tumor samples (Fig. 1A) . The CASC2 expression level was markedly decreased in the GC cell lines compared with the normal gastric epithelial cell line, GES-1 (Fig. 1B) . As SGC7901 and MGC803 exhibited relatively low endogenous CASC2 expression levels among all of the tested cell lines, these two cell lines were selected for the subsequent experiments.
Low CASC2 expression levels correlated with poorer survival.
In order to establish whether the expression level of CASC2 in GC tissues exerted an effect on patient clinicopathological features, the correlation between CASC2 expression level and clinicopathological features were further assessed. The 69 primary GC patients were divided into two groups based on the mean value of CASC2 in tumor tissue samples: A high-CASC2 group (n=34; CASC2 expression ratio >median) and a low-CASC2 group (n=35; CASC2 expression ratio ≤median). The associations between CASC2 expression level and the clinicopathological features are summarized in Table I . Notably, low CASC2 expression levels in GC samples were significantly correlated with vessel invasion (P= 0.016), advanced TNM stage (P=0.0063) and metastasis (P=0.034). However, no significant difference between CASC2 expression level and sex, age, tumor size, cell differentiation, or tumor site was identified. To determine the association between CASC2 expression level and the prognosis of GC patients, OS curves were plotted according to the CASC2 expression level and analyzed using the Kaplan-Meier method and log-rank test. The high-CASC2 expression group had significantly shorter OS than the low-CASC2 expression group (Fig. 2) . These results indicate that CASC2 may present as a useful marker of the prognosis or progression of GC. Table I . Correlation between lncRNA CASC2 expression and clinicopathological factors in gastric cancer patients. lncRNA, long non-coding RNA; CASC2, cancer susceptibility 2.
lncRNA CASC2 expression level ---------------------------------------------------
Overexpression of CASC2 inhibits GC cell proliferation in vitro.
To assess the biological role of CASC2 in GC, the effect of CASC2 on GC cell lines was evaluated. CASC2 was overexpressed by transfecting the pcDNA3.1-CASC2 vector into the SGC7901 and MGC803 cell lines, which contained the lowest expression level of CASC2. RT-qPCR analysis was performed 48 h post-transfection and the data revealed that ectopic overexpression of CASC2 significantly increased the expression level of CASC2 in SGC7901 and MGC803 cell lines (Fig. 3A) . To further identify the function of CASC2 on cell growth, cell proliferation and colony formation assays were performed. As shown in Fig. 3B , cell proliferation was significantly inhibited when CASC2 was overexpressed in the SGC7901 and MGC803 cells. Furthermore, compared with the control vector, CASC2-overexpressing SGC7901 and MGC803 cells markedly induced cell apoptosis. These data indicated that CASC2 acted as a tumor suppressor by suppressing proliferation and inducing GC cells. Overexpression of CASC2 inhibits GC cell invasion and angiogenesis. As a significant difference between the expression level of lncRNA CASC2, and vessel invasion and metastasis was identified, whether CASC2 is involved in GC cell invasion was then investigated. The invasion assay indicated that overexpression of lncRNA CASC2 significantly inhibited cell invasion in SGC7901 and MGC803 cells (Fig. 4A) . Furthermore, the results demonstrated that formation of capillary-like structures of HUVECs treated with CASC2-conditioned medium were significantly decreased (Fig. 4B) . These results revealed that CASC2 acted as a tumor suppressor via inhibiting cell invasion and angiogenesis.
Discussion
Various studies revealed that >10,000 lncRNAs are encoded by the human genome in integrative genomic analyses (18) (19) (20) . Despite rapid progress in screening, cancer-associated lncRNAs were observed to be involved in the development of cancer (16, 18) . Recent findings indicate that many lncRNAs act as oncogenes or tumor suppressors, and are important in GC (13, 21, 22) . H19, HULC, and SPRY4-IT1 were identified to increase in GC tissue samples and their knockdown strongly inhibited proliferation, migration and invasion of GC cells in vitro (23) (24) (25) . CASC2 was identified to be significantly downregulated in GC tissue samples and overexpression of CACS2 may inhibit GC cell proliferation via inactivation of the extracellular signal-regulated kinase 1/2 and c-Jun N-terminal kinase/mitogen-activated protein kinase signaling pathways (13) . However, the mechanisms underlying the aberrant expression of CACS2 in GC remain elusive. Consistent with previous studies, the present study indicated that the expression of CACS2 in GC tissue samples was significantly higher than that in corresponding non-tumor tissue samples. Furthermore, statistical analyses revealed that a low expression level of CACS2 in GC samples was associated with the depth of invasion, TNM stage and metastasis. Low CACS2 expression levels in GC tissues were associated with a short OS and may be an independent prognostic factor. These results indicate that CACS2 may function as a tumor suppressor in GC progression. Furthermore, it was identified that overexpression of CACS2 inhibited tumor cell proliferation by inducing cell apoptosis.
Transwell assay revealed that the overexpression of CACS2 decreased cell motility and angiogenesis. The present study identified a GC-associated lncRNA, CACS2, and elucidated its functional roles in GC development and progression. However, there is a lack of information regarding the underlying mechanism of CACS2; therefore, more experimental studies on CACS2 are required to provide important information to further our understanding of its functional roles in GC.
In conclusion, the present study indicates that CACS2 expression levels were significantly decreased in GC tissue samples when compared with healthy adjacent tissue samples, as well as GC cell lines. In addition, a low CACS2 expression level was associated with poor prognosis and may present as a negative prognostic factor for GC patients. The current data demonstrate that the migration and invasion ability of GC cells were significantly inhibited by the overexpression of CACS2, indicating CACS2 as an important regulator of metastasis. Thus, these data indicated an important role of CACS2 in the molecular etiology of GC and implicate the potential application of CACS2 in GC therapy. 
